Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to our speaker today, Matt Scalo. Please go ahead.

Thanks, Latania, and good afternoon, and welcome to the Myriad Genetics fourth quarter and full year 2024 earnings call. During the call, we will review financial results we released today. And afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in the Investors section of our website, along with the slide presentation. Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management's current expectations, and the actual events or results may differ materially and adversely from those expectations for a variety of reasons. We refer you to the documents the company files from time-to-time with the SEC, specifically the company's annual report on Form 10-K, its quarterly reports on Form 10-Q and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in our projections or forward-looking statements. And now, I turn the call over to our CEO, Paul Diaz.

Thanks, Matt. Good afternoon, everyone, and thank you for joining us. On today's call, we will discuss our fourth quarter and full year performance and provide an update on the progress we continue to make to accelerate profitable revenue growth and innovation in advanced diagnostics. First, I want to thank my Myriad teammates and our provider partners for their continued support and commitment to advancing our mission and vision to make genetic testing and precision medicine more accessible to help people take more control of their health. Delivering on our mission would not be possible without our Myriad teammates, who continue to recognize our company as a great place to work, with approximately 84% of our teammates rating us as such. Additionally, Forbes recently named Myriad in its list of best employers for 2025. Most everyone you meet at Myriad loves what they do, and we see it played out daily as our teammates go above and beyond to serve our provider partners and their patients. This is reinforced by our strong 72 Net Promoter Score, which captures how different external groups from providers to payers score their interactions with Myriad. Our active pipeline of innovative and clinically-relevant products is supported by the clinical studies and data that we continue to produce at an accelerated rate. As we continue to invest to bring new science to the marketplace, we continue to maintain industry-leading margins, achieve profitability and are seeing growth across the enterprise. I want to now highlight the progress that Myriad Genetics has made over the past five years. We're a very different company than when we started this journey in 2020, and our proven ability to innovate, grow organically and reap profitability has set us apart from many of our respected peers in the industry. Top tier science…

Thank you, Paul. I want to take a moment to recognize the hard work that you and our Myriad team have put in over the past 4.5 years to deliberately focus in on areas of strategic importance, divesting non-strategic assets, restructuring to get our cost basis under control, and shifting to invest and prioritize for growth. Thank you, Paul, for your leadership. Next slide. As we move forward into 2025 and beyond, we will continue to be guided by our mission to advance health and well-being for all, along with our commitment to delivering predictable, sustained, profitable growth. Four elements of our strategy in oncology, women's health and pharmacogenomics remain intact, as does our focus on providing an easy-to-use customer experience across our product portfolio from learning about our offerings to test ordering, to results delivery, along with patient and provider education and support. We will continue to increase our focus on innovation and providing relevant compelling product offerings for sizable, attractive market opportunities, where we can leverage Myriad's differentiated capabilities and right to win. We will also have a stepped-up focus on execution excellence across the company to support the achievement for our strategic intent and ongoing business and financial objectives. Next slide. MyRisk remains the gold standard in the market for hereditary cancer testing. Building on this cornerstone, our strategy in oncology remains to serve the continuum of patient care from screening and prognostics products including MyRisk and Prolaris to therapy selection with products including MyChoice Precise Tumor to monitoring and therapy adjustment, including Precise MRD for the most prevalent cancer indications including breast, prostate and ovarian. We will drive growth by focusing on products that are most needed by community oncologists and healthcare providers, leveraging our broad commercial reach and established reputation for quality and delivering diagnostic…

Thanks Sam for the kind words, trust and leadership. I also want to echo Sam's comments and thank Paul for his leadership, guidance and partnership over the last 4.5 years. Turning to Slide 17. Full year 2024 revenue grew 11% year-over-year and our ASP remained stable with 3% growth over the year. For the fourth quarter, hereditary cancer testing revenue increased 6% compared to last year, while prenatal revenue grew 12% over the same period. GeneSight continued to show strong demand as well, with revenues up 14% in the quarter. I do want to address our slower-than-expected volume growth in Q4. Our prenatal, GeneSight and affected hereditary business remained on-track, while our unaffected business slowed due to attention placed on the launch of Prequel at eight weeks gestational age and EMR workflow conversions taking longer-than-expected. Next slide. EMR solutions continue to be a key area of investment across our enterprise, as we seek to improve the customer and patient experience. Our efforts with EMR systems are making a difference in the way we engage with our customers and will be an important driver of future volume growth. As Sam has mentioned on previous calls over the past two years, we have doubled our investment in EMR through engineering, integration and commercial pull-through, resulting in more than 4,500 new clinic locations in 2024. We have system integration across 15 plus different vendors, including strategic partnerships with key EMRs like Athena, EPIC, Flatiron for Oncology and Lumia for Urology. This has been an incredible effort by all our teams, although we have seen workflow disruptions at certain health systems take longer to fully integrate and often take several quarters to stabilize and yield increased volumes. Next slide. In 2024, our women's health team delivered 14% revenue growth year-over-year, as we continue to…

Thanks, Mark. I'll start on the next slide. We are pleased with our continued progress this year, having generated 11% total revenue growth, including domestic revenue growth of 15%. This growth was driven across a number of areas, hereditary cancer testing revenues grew 11%, while prenatal and pharmacogenomics grew 17% and 23%, respectively. 2024 revenue growth also reflects the positive sustainable pricing environment, which we have highlighted on past calls. Regarding fourth quarter results, total revenue grew 7% year-over-year. Domestic revenue grew 11% in the quarter partly offset by the Q3 of '24 divestiture of our EndoPredict business in Europe, which removes approximately $11 million of annual run rate revenue. Mark addressed the commercial dynamics affecting Q4 volume growth, and I reiterate our belief that test volume growth in hereditary cancer and prenatal will reaccelerate as the year progresses. We did benefit modestly from a favorable change of estimates from prior periods in Q4, but the amount was less than either Q3 of '24 or Q4 of '23. Next slide. We have been highlighting key drivers for sustainable progress and average revenue per test, including various investments and initiatives by both our revenue cycle and payer markets teams. These include, among other things, working with health plans to encourage their implementation of medical policies that can form the state biomarker legislation. There is a growing list of states that have passed biomarker legislation that lends itself to ensuring access to precision medicine and advanced diagnostics. Generally, no one of these wins is likely to have a material impact on revenue but we certainly expect the accumulation of many small and medium-sized wins over time to contribute to the rate environment for our products. In Q4, we again saw stability in underlying rates across our portfolio, which represents another proof point…

Thanks, Scott. I'd like to close by saying thank you to our Board of Directors for the opportunity to serve here at Myriad Genetics for the past 4.5 years. To my colleagues in the industry, and to everyone in the investment community on the line today, we're helping me to learn advanced diagnostics and your advice over the years. And most importantly, to my Myriad teammates for their commitment and friendship as we work together to reset Myriad's Genetics culture, our foundation for continued growth, innovation and value creation for all of our stakeholders. I'll now pass it back to Matt for Q&A.

Thanks, Paul. And as a reminder, during today's call, we use certain non-GAAP financial measures. A reconciliation of the GAAP to non-GAAP financial results and a reconciliation of GAAP to non-GAAP financial guidance can be found in our earnings release and under the Investor Relations section of our website. Now we are ready to begin our Q&A session. To ensure broad participation, we're asking participants please ask only one question and one follow-up. Latania, we are now ready to address the Q&A portion of this call.

[Operator Instructions] Our first question will be coming from Doug Schenkel of Wolfe Research.

This is Madeline Mollman on for Doug. Just wanted to touch on the operating expense. On the 25% increase in R&D spend, should we assume this is primarily allocated towards criminal evidence generation for Precise MRD? And given this increase, is it reasonable to assume that SG&A would decline year-over-year to align with the overall OpEx guidance for 2025? And then are you still targeting 1,000 basis point SG&A reduction by 2026 versus 2023?

So yes, the quarter definitely reflected our acceleration of our investments in clinical studies in advance of the launch of FirstGene and Precise MRD, where we're continuing to be excited about the studies that should come out this summer. As referenced earlier in the call and in the earnings release, we've made certain changes in our operating cost model that to reflect the UnitedHealthcare payment changes. So across commercial, SG&A and R&D. But I think what you will see is a 25% increase in R&D to support future growth, about an 8% increase in our technology spend and belt tightening elsewhere in the organization for overall pretty modest 3% increase, Scott, I think we're forecasting year-over-year. So I think that just reflects our ongoing discipline about operating expense management dealing with the UnitedHealthcare change in a pragmatic way, but reallocating our investment dollars for future growth.

Our next question will be coming from Matt Sykes of Goldman Sachs.

This is Will Ortmayer on for Matt. Just wanted to shift over to hereditary cancer. With the unaffected market still around 10% penetrated, you mentioned some good traction in your breast cancer risk assessment program recently. Can you talk a little bit more about the progress you're making in that affected market and the runway you're seeing for sustained growth there?

Yes. As we said in the call, I mean, we think that is a real sweet spot for Myriad. We think we have a competitive advantage with our breast cancer risk assessment program and we are gaining traction in a large part, a lot of that EMR integration that we talked about will help fuel that. I think -- but as we also mentioned, as you can imagine, switching workflows, especially in the unaffected market where it requires a lot of patient education, it requires gathering family history. There's a lot of ancillary parts other than just ordering the test, but we see a lot of future growth. And as you mentioned, it's only 10% penetrated. And so that is definitely an area that we're excited about moving forward into 2025, not to mention, as Sam mentioned, the 50 million women who really can benefit by getting hereditary cancer testing.

And then just a follow-up. You mentioned some opportunity from the recent market dislocation in that space. Has that been playing out for you to start the year? And how big of a tailwind could those share gains be throughout the year?

So as we said last quarter, the integration with Labcorp really just sort of happened here in January. In terms of potential impact for customers, Labcorp does a fine job, but that certainly presents an opportunity for people that are looking for a different experience. The Ambry acquisition by Tempus just occurred a couple of weeks ago. And so typically, these kinds of changes in the marketplace take several quarters to sort of play out. But they do provide an opportunity for us, given our value proposition about reliability, consistency, accuracy, fast turnaround times to gain share in these markets, particularly in hereditary cancer.

Our next question will be coming from Tejas Savant of Morgan Stanley.

This is Madison on for Tejas. Just want to start off. As we look out to the next year, how should we be thinking about revenue phasing? And is there any seasonality we should be keeping in mind and just giving us maybe a little bit of a sense of weighting between first half and second half?

Yes. I mean, generally, I would say -- we made some comments on the call about expecting an acceleration in the volume growth trajectory in the second half of the year based on some of these initiatives, including accelerating ramp from EMR. So that, I think, will weigh a little bit more heavily towards the second half of the year. Other than that, I would say, bear in mind some of the typical seasonality that we see as a business, and we have talked in the past about, for example, Q3 being a relatively lighter quarter and Q4 being a relatively stronger quarter.

Yes. Q2 and Q4 are typically where we see a little bit more bounce.

And then previously, I know you discussed MyChoice CDx experiencing a bit of underperformance to the disruptions in Europe giving the AstraZeneca decentralization of their product? I was just wondering if you could kind of speak to the trends you're seeing there now for MyChoice and what assumptions you have baked into the guide for how to test should perform during the year.

Yes. I would say that most of that change is behind us. And so we expect to see stable to modest growth of. MyChoice going forward. The thing that we're the most excited about MyChoice is expansion to other indications where we're making progress to expand beyond ovarian to breast and prostate much bigger TAMs. And so that's very, very little in terms of growth in 2025 is based on MyChoice. But the expansion of indications really set us up well for bigger growth in '26 and '27.

Our next question will be coming from Subbu Nambi of Guggenheim.

This is Thomas on for Subbu. Just one on Prolaris. So thinking about NCCN guideline updates and the confusion in recent months. Just curious where your focus is with Prolaris today and where can you add the most value this year for growth in that test?

Yes. I think there's a couple of things. Number one, we continue to work with our KOLs as we mentioned on the call, as well as those that are in charge of writing the guidelines to potentially get that confusion removed. So I think that's sort of step own. I think step two, as we said, we are increasing our investments across marketing, medical affairs, KOL engagement, across the board because we're excited not only about where our product sits today, but as well as the announcement that we made with PATHOMIQ and our ability to bring the pairing together of AI as well as Prolaris. And then as we also mentioned, also within those guidelines was our ability to bring MyRisk precise tumor also to the table. So we see this as an area that we're going to strongly invest in, and we expect growth in the future.

And then my second one is on GeneSight. So over the last couple of months, Myriad has made it a point to get out in front of investors and customers, following some '24 decisions that didn't go your way. Curious if you can share what that time has been spent in terms of where you're spending your attention on your sales force? Or is it being more customer-facing? Or is that time spent in front of commercial payers? And then where have you seen the most benefit given the situation and where will you continue to aim your focus this year?

Yes. Let me clarify. So the sales force hasn't changed its focus at all, right? So the sales force remains completely focused on those providers that are treating menohalt patients, and they've been continuing to do that which is why the GeneSight demand continues to remain strong, why they're the market leader, but also unfortunately, because of the mental onus crisis that is happening today. Internally, as an executive team, we've been working with United. We've had our different medical affairs teams working on data evidence generation as well as our government affairs team working with advocacy support and so on. So two very completely separate things. And we think that's the way it needs to be so that we can remain focused and we can make sure that the patients who need GeneSight continue to get GeneSight while we continue to work through this.

Yes. Maybe to up-level the answer a little bit. As Mark stated, and I think sort of implicit your question, we continue to see strong demand for GeneSight. And so our market approach really hasn't changed. But we continue to see as the opportunity to mitigate the UHC policy change. Again, putting aside our continued work with UHC to carve out or reverse that policy is our biomarker legislation and our advocacy efforts there, which, again, we're investing more in time and energy in. And I would just underscore sort of two things. We have not seen -- as we sit here today on February 24, any effect on this with respect to GeneSight volumes, and we have not seen any impact on our Prolaris volumes because of some of the confusion around NCCN guidelines. And in fact, as Mark stated, the underlying strategic premise that Sam spoke to of our ability to bring a comprehensive set of offerings in prostate cancer around places is really the future opportunity in this company that we're most excited about.

Our next question will be coming from Tycho Peterson of Jefferies.

I just want to go back to Prolaris for a minute. I mean, can you maybe walk through the exact steps you think you need to take care to get to Level 1b in guidelines? And do you think this is viable, is there a time line on this? And can you -- I know you don't guide for Prolaris, but can you actually give us some sense of what you've baked into numbers, just given all the moving pieces around it.

Maybe I'll take the first part, Mark, you can take the second part. As it relates to getting Simon Level 1 evidence, I think we've been pretty open about it. One of our challenges has been access to the samples that are needed to get that designation partnership now with PATHOMIQ who has this deep seated set of relationships. They started with prostate cancer. And we are excited, and we're seeing receptivity to the -- working with us when you have a combination of clinical collaboration, which includes not just molecular, which is our base of Prolaris, that combined with the AI element that PATHOMIQ brings. So we haven't quantified yet, give us just a little bit of time. We announced the collaboration formulary this morning, but we are confident that the time lines, which we have been working under are going to be accelerated. And we look forward to sharing more of that with you in the upcoming months.

And as you said, Tycho, we don't guide at the individual product level. But what I can tell you is that we are expecting growth revenue and volume growth from Prolaris in 2025.

And our next question will be coming from Sung Ji Nam of Scotia Bank.

I'll just ask my questions together. Just we're hearing more and more about these kind of AI-enabled testing technologies, capabilities, et cetera. So just kind of curious, with this exclusive partnership with PATHOMIQ, why is PATHOMIQ the right partner? Is the multimodal testing approach pretty unique to what you guys are trying to do? And then what do you think differentiates the different AI technology platforms out there? Is it just the access to the amount of data, patient data that you have? Or is it just some sort of differentiated technology, AI technology platform that kind of provides a competitive advantage?

Yes. Thank you very much for the thoughtful question. I'd start off by saying, by the way, we've been employing AI in various parts of operations for a long time, including a lot of our pipelines, for variant calling and so forth. But to your question, why PATHOMIQ? What really gets us excited is we were doing our diligence to look at potential partners is really related to the fact, again, I'll restate PATHOMIQ started with prostate cancer. That's where they have deep roots. If you look at the PATHOMIQ team, there are a number of folks. This is what they've done for their entire career. Beyond that, the established relationships that they have with leading members, institutes that are 100% focused on prostate cancer, that gives not only the ability to access the samples, but it also gives once again, a broader network we're 100% focused on prostate. So for us, it's the combination of that, together with the IT position as we looked at what they have, which we believe is strong and gives us together the freedom to operate and to build on. And we've been impressed also -- we haven't talked about this yet today. The actual product, the way it will be brought to market will be able to start from H&E staining. And as you might know, in pathology, H&E staining that's the most foundational or fundamental way of staining being able to start from those slides, digital images, to then be able to bring the proprietary AI algorithm for the analysis and interpretation which could all be in the partnership, which Myriad will then be able to handle, leveraging our commercial channel and our customer service. We think that combination with our channel is what really allows us to feel confident. One further thing, we've, been spending time looking at options and opportunities for some period of time, including doing pilots with PATHOMIQ to gain the confidence that they are the right partner. So we couldn't be more thrilled with Rajat, the CEO and that team and looking forward to a very exciting partnership, which we'll be able to share more about in the coming months.

Our next question will be coming from Bill Bonello of Craig-Hallum.

I guess just a question on the CEO transition, which isn't necessarily surprising given the timing of when you brought Sam and Scott on and you've been asked about it a lot. I think over the course of the last year. But maybe you could give us some sense of why is now the right time? Or maybe if I ask it a little bit differently, why is it not the wrong time right now?

Well, it certainly would have felt a lot better before the United decision but, the truth is that Sam has done an exceptional job here as is Mark. And there's always more work to be done. There's always more opportunity. But this is a personal decision for me and my family. And I've got an opportunity to join Cressey & Company as a managing partner, which is not typically when an operator like me gets to go do for his last chapter. And so that's really what drove the timing my confidence in our strategy, and this team and the platform that we have built, the opportunities that we have are significant. And so never a perfect time, but it was the right time given the opportunity that was presented to me personally and the significant runway that Sam and Mark and the rest of the teams have here.

That's helpful to understand that it was sort of driven by the timing of your opportunity as well. I guess just -- go ahead.

No. Yes. I mean that really was what may have been a year from now or something like that was driven by the opportunity today to pursue this opportunity for myself and for my family.

And then maybe just in terms of the Q1 commentary, obviously, it wasn't that long ago that you updated your full year guidance. And again, it was early in the quarter, we kind of had every opportunity to talk about Q1. I guess I'm just trying to get a feel for this. I mean, are you characterizing Q1 as a typical Q1 or some of the commentary I heard over the course of the call, made me feel like maybe the year isn't getting off to quite as good a start as you would have hoped it was. So if you can just kind of characterize that a bit.

Well, just to clarify, I'm sorry if I misunderstood your question, but we had made previously commented about the full year. We had not previously made any comments about Q1 expectations.

That's what I said. You could have, but you didn't.

Yes. I mean I think it would have just been premature for us to do that, quite frankly. But really, if you go back to the comments that I made, one of the areas that I flagged was that we did have a fairly significant favorable out of period in Q1 of last year. And so certainly, there's always a possibility that you could get a repeat of something like that continues to provide a tailwind. But where we sit today, we just -- we feel like that is going to make it a more difficult comp on the quarter. And then obviously, we're still ramping in some of the other areas that Mark highlighted during the call.

Okay. So I mean, in terms of if the year is getting off to sort of how you hoped it would, I mean, the comp was always there. So just curious how you've characterized how that’s going relative to your expectations?

Yes. We reiterated our full year guides and nothing has changed in that respect. And as we said, we have been expecting a ramp that would accelerate throughout the year.

Nothing has changed from when we gave initial guidance in our views of the year or, quite frankly, the seasonality that we typically see in the quarter. You have co-pays and deductibles. If you look back over the last couple of years, Bill, as we talked about earlier on the call, you typically have Q1, Q3 seasonality.

Yes, I get that. And obviously, nobody brought their consensus numbers down after your guidance. And so that's part of the disconnect there --

Well, the fact is like half have not updated their consensus numbers is a little bit of a challenge. But yes, we scratched our heads about that.

Our next question will be coming from Puneet Souda of Leerink Partners.

So listen, so my question is really looking -- forward, just -- diagnostics has been relatively spared so far, fingers crossed just given all of the concerns out there. But just -- and questions out there. But just can you elaborate a little bit on the Medicaid exposure? And I'm just trying to understand how much of a risk would that be if new administration pursues some Medicaid spending cuts?

Yes. If you think about Medicaid spending cuts as a consequence of block rates or anything and where our Medicaid reimbursement comes from, it's mainly going to be in prenatal. And that is not historically where -- and I've been on the other end of Medicaid cuts in many other sectors, not where state legislatures go. So look, there's a lot of questions in terms of policy right now. But when we look at the distribution of our revenues in terms of Medicare, commercial and Medicaid and where in our products, the Medicaid revenue falls, we don't think we have a lot of exposure to Medicaid block grants or some other changes in Medicaid reimbursement.

And then maybe, first then. I mean, just looking at the portfolio, can you maybe just elaborate on how you're prioritizing investments. And again, when we're thinking about potential opportunity? There's ACOG and for NIPT, other things that could potentially be tailwinds despite the headwinds that you're seeing in the marketplace. So maybe just elaborate what are some focus areas for you investment-wise?

Yes. Thank you, Puneet. That's a great question. As I mentioned, at this point, I feel privileged that I've been an important part, along with Mark and Paul and Scott and others of developing our strategy and areas of focus, right? So in the near term, at least, there is no intention of changing our strategy or focus. You're right. When you talk about we are excited. We've already developed our expanded carrier screening, Foresight universal Plus product. So we're ready to catch the wave, if you will when ACOG guidelines are updated, that's exciting for us. And oncology remains another probably at the heart of the company still a great opportunity to build on the cornerstones that we have, and it's not just MyRisk, it's MyChoice. We are the HRD gold standard. And we're looking at other opportunities to take HRD broader into the market. We announced with Illumina. I think a few months ago, how it will get integrated into their TSO kits as well. But really, it's serving the continuum of cancer care. I'll go back to that. Right, really filling out those gold standard positions with new offerings, which allow us to look at therapy selection with precise tumor to build on that, to get a liquid solution for therapy selection in the market in 2026 as well. And of course, there is -- continues to be a lot of real engagement and work on MRD. Again, our first indication that we're going to bring a product to market is going to be breast cancer. And we have nearly 20 different clinical studies in MRD that are underway and a total of more than 4,000 patients that either are in the process of being enrolled. And since you look at multiple data points in the journey of a patient looking at remission and relapse, we're talking at over 30,000 data points so the focus there and then the opportunity again is really about the continuum of cancer care. And the partnership like that we announced with PATHOMIQ, which we're very excited about, complements what we have to give us a solution where, honestly, we were not participating already, right, excuse me, we were not participating today in post-radical prostatectomy. So we're going to have a solution there by the end of 2025 with our partnership, very excited about that. And just kind of a foreshadowing, I think I mentioned in my prepared remarks, we understand that along with the great organic work that we do, that there's opportunities to get to market faster with select deep partnerships. So PATHOMIQ is a great example, but there will be more to come. That allows us to accelerate the path that Myriad has been on organically.

And one moment for our next question. Our next question will be coming from Ben Mee of Stephens.

This is Ben on for Jason. So I just want to start with the launch of Prequel at 8 weeks there. I was hoping you'd be able to provide some commentary sort of on what you're hearing from the docs there. Just really how that adoption and merger reception has been.

Yes. Let me just frame it by. We launched it in November of last year. So we're still in early innings. But as I called out on the call, One of the keys within that space is that first OB visit is typically is at 8 weeks. And so historically, when you've got a 10-week test or you got a 12-week test, that kind of disrupts workflows, it's not the best for the patient, its certainly the best for the provider. So we've seen a lot of excitement about it. And it is something very unique because of our Amplify technology. So Prequel was always sort of one of the best tests out there. So now that it is at 8 weeks, we're seeing a lot of acceptance. And you will hear more from us in the upcoming quarters. It's just still a little early for us to really comment and get into more details.

And I believe you pointed to sort of in 2025, double-digit growth in hereditary cancer testing volumes and have guided stable ASPs there. One, can you confirm this? And then with some of the initiatives that --

I don't think we've guided to -- you're breaking up, sorry. I mean, we haven't guided to specific volume numbers, we -- Scott has talked about stable ASPs and hopefully continued contribution there, a couple of percentage points if we continue to execute. But we don't guide on specific volumes for any products.

Our next question will be coming from Tycho Peterson of Jefferies.

Yes. Just a question on the LRP. The language here is changing a little bit. You're going from 12% to double-digit revenue growth. Can you maybe comment on that?

Well, we took a $45 million run rate hit for United. So that's kind of knocked us back a little bit. So -- and GeneSight has been a big contributor to our growth, 23% this past year. So we still have a long-term growth objective of 12%, but we think in the intermediate term, getting back to double digit in '25 and growing from there.

Yes, I was commenting specifically on the 2026 and beyond guidance that you have on the slides.

Yes. Again, we'll be launching new products in '26, but you are correct. We have because of the contribution of GeneSight and because it will be early in the launches of FirstGene and Precise MRD, we have modified that to double-digits, call it 10%, as opposed to 12%, obviously, with our expectation that we can get back there quickly. But we were certainly on that path to that and beyond before we sustain the United piece. And I just want to underscore that we continue to work with United on what we think was an error in their policymaking process here. And as Mark talked about, we'll continue to submit clinical evidence and engage with them and hopefully, certainly by the end of the year, when they revisit their policy, we'll have submitted 2 or 3 different studies that underscore the value proposition of GeneSight and quite frankly, get at a couple of the points that people have criticized vis-a-vis the PRIME study and other things.

I would now like to turn the conference back to Matt for closing remarks.

Okay. Thanks, Latania. This concludes our earnings call. A replay will be available via webcast on our website for one week. Thank you again for joining us and have a good afternoon.

And this concludes today's conference call. Thank you for participating. You may now disconnect.